Elizabeth Nguyen, MD
Nephrology · Atlanta, GANPI 1629000344
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,304 of the $7,346 with a category attached, or 85.8%. It is spread thinly across 30 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,275 and has fallen 70.2% since, to $678 in 2025.
Across 317 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$852
- Vifor Pharma, Inc.$647
- Bayer$599
- Fresenius USA Marketing, Inc.$542
- Amgen$527
- plus $3K from 24 others
Across 19 payments — averaging $25,400 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$194K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$160K
- Eli Lilly$88K
- Novartis$41K
What the payments were for
- Travel & lodging$79211%
- Food & beverage$6,30486%
- Education$2503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $1,226 |
| AstraZeneca(2 entities) | 42 | $852 |
| Vifor Pharma, Inc. | 34 | $647 |
| Bayer | 26 | $599 |
| Fresenius USA Marketing, Inc. | 42 | $542 |
| Amgen(2 entities) | 27 | $527 |
| Otsuka America Pharmaceutical, Inc. | 17 | $352 |
| Daiichi Sankyo Inc. | 17 | $320 |
| Mallinckrodt Hospital Products Inc. | 10 | $311 |
| Akebia Therapeutics Inc | 13 | $295 |
| Novo Nordisk | 7 | $263 |
| Aurinia Pharma U.S., Inc. | 9 | $239 |
| OPKO Pharmaceuticals, LLC | 14 | $228 |
| Calliditas Therapeutics US Inc. | 10 | $213 |
| GSK | 9 | $175 |
| Lilly USA, LLC | 5 | $80 |
| Vertex | 1 | $73 |
| ANI Pharmaceuticals, Inc. | 3 | $67 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Baxter Healthcare | 2 | $43 |
| Boehringer Ingelheim | 2 | $39 |
| AMAG Pharmaceuticals, Inc. | 2 | $34 |
| Sanofi | 1 | $32 |
| Pfizer | 1 | $30 |
| Ardelyx, Inc. | 1 | $23 |
| Lemaitre Vascular, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$111
How this compares
$7,346 in reported general payments places this provider in the 85th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 68 | $57,591 |
| KerendiaFinerenone | 40 | $53,603 |
| VelphoroSucroferric Oxyhydroxide | 12 | $42,827 |
| ProcritEpoetin Alfa | 17 | $19,955 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $18,712 |
| Sevelamer Carbonate | 74 | $13,790 |
| EpogenEpoetin Alfa | 16 | $12,420 |
| JardianceEmpagliflozin | 11 | $12,396 |
| ProsolParenteral Amino Acid 20% No.1 | 53 | $7,880 |
| Clonidine | 25 | $4,688 |
| Febuxostat | 29 | $3,911 |
| Nifedipine ErNifedipine | 64 | $2,666 |
| Calcitriol | 152 | $2,631 |
| Hydralazine Hcl | 158 | $2,490 |
| Metolazone | 39 | $2,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $852 | $76,30487 claims |
| BayerKerendia | $599 | $53,60340 claims |
| Fresenius USA Marketing, Inc.Velphoro | $542 | $42,82712 claims |
| AmgenEpogen | $527 | $12,42016 claims |
| Boehringer IngelheimJardiance | $39 | $12,39611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 388 nephrology providers in Georgia.
Other nephrology in Atlanta
- Sheldon ShoreAtlanta$474K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Frederic Rahbari OskouiAtlanta$88K
- Tarik LalwaniAtlanta$69K
- Haimanot WasseAtlanta$60K
- Janice LeaAtlanta$21K
- Vandana NiyyarAtlanta$11K
- Gautham ViswanathanAtlanta$10K
- Lara WatkinsAtlanta$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.